Research article | Open | Published:
NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner
Journal of Molecular Signalingvolume 5, Article number: 4 (2010)
Ovarian cancer is the leading cause of death among gynecological cancers. Cisplatin is one of the most effective anticancer drugs used in the treatment of ovarian cancer. Development of resistance to cisplatin limits its therapeutic use. Most of the anticancer drugs, including cisplatin, are believed to kill cancer cells by inducing apoptosis and a defect in apoptotic signaling can contribute to drug resistance. The tumor suppressor protein p53 plays a critical role in DNA damage-induced apoptosis. During a yeast-based drug screening, NSC109268 was identified to enhance cellular sensitivity to cisplatin. The objective of the present study is to determine if p53 is responsible for cisplatin sensitization by NSC109268.
NSC109268 enhanced sensitivity of ovarian cancer 2008 cells and its cisplatin resistant counterpart 2008/C13* cells which express wild-type p53. The potentiation of cisplatin sensitivity by NSC109268 was greater in 2008/C13* cells compared to 2008 cells. Cisplatin caused a concentration-dependent increase in p53 in 2008 and 2008/C13* cells, and the induction of p53 correlated with cisplatin-induced apoptosis as determined by the cleavage of PARP. NSC109268 alone had no effect on p53 but it enhanced p53 level in response to cisplatin. Knockdown of p53 by siRNA, however, did not attenuate cell death in response to cisplatin or combination of NSC109268 and cisplatin.
These results demonstrate that NSC109268 enhances sensitivity of ovarian cancer 2008 cells to cisplatin independent of p53.
cis-Diamminedichloroplatinum(II) or cisplatin is one of the most important anticancer drugs used in the treatment of solid tumors, especially ovarian, testicular, cervical and small cell lung carcinomas. Dose-limiting toxicity to normal tissues and acquisition of resistance by tumor tissues to cisplatin, however, poses a significant problem in cisplatin therapy. Identification of agents that can sensitize tumor cells to cisplatin, and circumvent or prevent cisplatin resistance should have significant impact in cisplatin-based therapy.
The anticancer activity of cisplatin is believed to be due to its interaction with chromosomal DNA . However, only a small fraction of cisplatin actually interacts with DNA, and inhibition of DNA replication cannot solely account for its biological activity . The effectiveness of anticancer agents depends not only on their ability to induce DNA damage but also on the cell's ability to detect and respond to DNA damage [3, 4]. The tumor suppressor protein p53 plays a critical role in DNA damage signaling . It is activated in response to DNA damage and triggers transcription of genes involved in cell cycle, apoptosis, senescence and DNA repair [6, 7]. The p53 gene is mutated in 50% of human cancers, and it is often inactivated by oncogenic viruses in those cases in which p53 is not mutated [8–10]. For example, the majority of cervical cancer cells contain wild-type p53 but the E6 gene product of human papilloma virus (HPV) results in the rapid degradation of p53 through the ubiquitin proteasome pathway . Thus, these cells have the same functional consequences as a mutated p53 gene.
NSC109268 was found to enhance sensitivity of budding yeast Saccharomyces cerevisiae during a novel yeast-based genetic screening of the Diversity Set compound library provided by the Developmental Therapeutics Division (NCI). It also increased sensitivity of human cancer cells to cisplatin . In the present study, we have examined the ability of NSC109268 to sensitize parental and cisplatin-resistant variants of p53-positive ovarian carcinoma 2008 and p53-null human cervical carcinoma HeLa cells to cisplatin. NSC109268 enhanced sensitivity of human ovarian carcinoma 2008 cells to cisplatin but it had no effect on the sensitivity of HeLa cells. However, the mechanism of cisplatin sensitization by NSC109268 did not involve p53.
Effect of NSC109268 on cisplatin sensitivity
We compared the ability of NSC109268 to sensitize human ovarian cancer 2008 and human cervical cancer HeLa cells and their cisplatin-resistant counterparts HeLa/CP and 2008/C13* cells, respectively. Figure 1 shows that NSC109268 enhanced the sensitivity of both parental 2008 cells and cisplatin-resistant variant 2008/C13* cells to cisplatin although the effect was more pronounced with 2008/C13* cells. When 2008 cells were treated with different concentrations of cisplatin alone for 72 h, the IC50 for cisplatin was 0.8 μM and it decreased to 0.5 μM when treated with both NSC109268 and cisplatin. The IC50 of 2008/C13* cells for cisplatin was greater than 10 μM and decreased to 2.8 μM when NSC109268 was included with cisplatin. In contrast, NSC109268 did not influence the sensitivity of parental HeLa and cisplatin-resistant variant HeLa/CP cells to cisplatin (Figure 2). Thus, NSC109268 enhanced the sensitivity of p53-positive ovarian cancer 2008 cells, and it had greater effect on cisplatin-resistant variant compared to parental drug-sensitive cells.
Effect of NSC109268 on cisplatin-induced p53 level
Since p53 plays a critical role in DNA damage signaling, we compared the effects of cisplatin on the cleavage of PARP and p53 induction in 2008 and 2008/C13* cells. Figure 3 shows that cisplatin caused a concentration-dependent increase in PARP cleavage in 2008 cells but not in 2008/C13* cells. Cisplatin also caused a concentration-dependent increase in p53 level in both 2008 and 2008/C13* cells but much higher concentrations of cisplatin were required to induce p53 in 2008/C13* cells compared to 2008 cells. Thus, the induction of p53 by cisplatin was associated with an increase in cisplatin-induced apoptosis in 2008 cells as determined by the cleavage of PARP. 2008/C13* cells were resistant to cisplatin-induced apoptosis.
To determine if NSC109268 sensitizes these ovarian carcinoma cells to cisplatin via p53-dependent mechanisms, we treated 2008 and 2008/C13* cells with the combination of NSC and cisplatin, and monitored p53 level and PARP cleavage. In this experiment, we treated 2008 and 2008/C13* cells with 1 μM and 40 μM cisplatin, respectively that had no effect on PARP cleavage at 24 h (Figure 3). As shown in Figure 4, cisplatin caused a substantial increase in p53 in both 2008 and 2008/C13* cells but NSC109268 alone had little effect on p53 induction. A 24 h treatment with NSC109268 and cisplatin caused a modest increase in p53 in 2008/C13* cells but not in 2008 cells. A 48 h treatment with NSC109268 and cisplatin increased p53 in both 2008 and 2008/C13* cells but the effect was more pronounced in 2008/C13* cells. A 24 h treatment with cisplatin had little effect on PARP cleavage even when coincubated with 2 μM and 3 μM NSC109268. A 48 h treatment of 2008 cells with 1 μM cisplatin caused PARP cleavage, which increased modestly by the inclusion of NSC109268. While 48 h treatment of 2008/C13* cells with 40 μM cisplatin alone had no effect on the cleavage of PARP, the combination of NSC109268 and cisplatin induced cleavage of PARP in 2008/C13* cells.
We also examined the effect of NSC109268 on cisplatin-induced cell death by staining cells with Yo-Pro-1 and propidium iodide (PI). The green-fluorescent dye Yo-Pro-1 can enter apoptotic cells, whereas the red fluorescent dye PI can only enter dead cells. Thus, when cells are stained with both Yo-Pro-1 and PI, apoptotic cells show green fluorescence whereas dead cells show primarily red fluorescence and some green fluorescence. As shown in Figure 5, NSC109268 enhanced cisplatin-induced cell death in 2008/C13* cells but had only a modest effect on cisplatin-induced cell death in 2008 cells.
Effect of p53 knockdown on the sensitization of cisplatin-induced cell death in 2008/13* cells
To determine if potentiation of cisplatin-induced cell death by NSC109268 was due to upregulation of p53 in 2008/13* cells, we examined the consequence of p53 depletion on the effects of NSC109268 on PARP cleavage and cell death triggered by cisplatin. Figure 6A shows that knockdown of p53 by siRNA effectively depleted p53 and little p53 could be detected following treatment with cisplatin. p53 was induced following treatment with NSC109268 and cisplatin even when cells were transfected with p53 siRNA albeit at much lower level compared to cells transfected without or with control siRNA. However, knockdown of p53 had little effect on cisplatin sensitivity or potentiation of cisplatin-induced PARP cleavage.
We also monitored cell death by staining cells with Yo-Pro-1 and PI staining (Figure 6B). Knockdown of p53 failed to prevent cisplatin-induced cell death in 2008/C13* cells. If anything, p53 depletion caused a slight increase in cisplatin-induced cell death. Moreover, p53 knockdown had no effect on the potentiation of cisplatin-induced cell death by NSC109268. Thus, NSC109268 enhanced cisplatin-induced cell death via p53-independent pathway.
Cisplatin has been very effective for the treatment of gynecological cancers, such as ovarian and cervical cancers. However, the development of resistance in initially responsive tumors to cisplatin is a major obstacle in cisplatin-based therapy. We inadvertently discovered that NSC109268 sensitizes budding yeast Saccharomyces cerevisiae to cisplatin . The results of our present study demonstrate that cisplatin-resistant ovarian cancer 2008/C13* cells are exquisitely sensitive to combined treatment with NSC109268 and cisplatin. We have utilized three independent methods to assess the effects of NSC109268 on cisplatin sensitivity-MTT assay, PARP cleavage and Yo-Pro-1/PI staining. Using all three assays, we have found that NSC109268 had a greater effect in augmenting the sensitivity of cisplatin-resistant 2008/C13* cells to cisplatin compared to its drug-sensitive counterpart.
Most of the anticancer drugs kill cancer cells by inducing apoptosis and a defect in apoptotic signaling could contribute to drug resistance. p53 plays a critical role in eliciting cellular responses to DNA damage, and is frequently mutated in ovarian cancers [12, 13]. It has been reported that the status of p53 is an important determinant of cisplatin sensitivity in patients with ovarian cancer [14–16] although some studies suggest that cisplatin-induced cell death is independent of the presence of wild-type p53 . An aberration in p53 has also been implicated in cisplatin resistance [11, 18–20]. Introduction of wild-type p53 by adenovirus vector sensitized ovarian cancer cells to cisplatin [21–23]. In the present study, we have used ovarian cancer 2008 cells and its cisplatin-resistant variant 2008/C13* cells which contain wild-type p53. Cisplatin caused induction of p53 in both parental and cisplatin-resistant 2008 cells and the increase in p53 correlated with cisplatin-induced apoptosis (Figure 3). In addition, sensitization of 2008/C13* cells by NSC109268 was associated with an increase in p53 level (Figure 4). Furthermore, NSC109268 failed to sensitize parental and cisplatin-resistant HeLa cells in which p53 is degraded by the human papilloma virus E6 (Figure 2). These results are consistent with the notion that NSC109268 sensitizes ovarian cancer 2008 cells to cisplatin via p53-dependent mechanisms. Following observations, however, argue against the involvement of p53 in the potentiation of cisplatin sensitivity by NSC109268.
Although little p53 could be detected in parental HeLa cells, we have found that p53 is detectable in HeLa/CP cells and it is further increased by the treatment with cisplatin . Perhaps low level of cisplatin-induced DNA damage during the selection of HeLa/CP cells stabilizes p53. We have also found that the level of HPV E6 protein, which degrades p53 is less in HeLa/CP cells . To determine if p53 is responsible for cisplatin sensitization by NSC109268, we depleted endogenous p53 by siRNA silencing. Knockdown of p53 had little effect on cell death by cisplatin or combination of NSC109268 and cisplatin (Figures 6A and 6B). Interestingly, depletion of p53 appears to increase cisplatin-induced cell death in 2008/C13* cells (Figure 6B). These results are consistent with earlier reports that inactivation of p53 may enhance sensitivity of cisplatin-resistant ovarian cancer cells to cisplatin .
The effect of NSC109268 on cisplatin sensitivity depends both on the concentrations and duration of exposure to these compounds. While a 24 h treatment with 3 μM NSC109268 alone had little effect on cell survival, a 72 h treatment with ≥ 3 μM NSC109268 caused a substantial decrease in cell growth as determined by the MTT assay (data not shown). The effect of NSC109268 on cell growth inhibition was much more pronounced in 2008/C13* cells compared to 2008 cells . In both yeast and ovarian cancer cells, NSC109268 appears to inhibit progression of cells from the S phase to G2/M phase . Thus, cells arrested at the S phase may be more sensitive to cisplatin. Additionally, we have found that in response to cisplatin, a substantial fraction of 2008/C13* cells were stained with the cell impermeable dye propidium iodide. Since these cells are resistant to apoptosis, it is conceivable that NSC109268 increased cisplatin-induced cell death by enhancing cisplatin-induced necrosis via p53-independent pathway.
The mechanisms of cisplatin resistance are multifactorial and include decrease in drug uptake, increase in DNA repair, increase in cellular thiol content, defect in p53 and increase in antiapoptotic signaling . The protein kinase C (PKC) signaling pathway plays an important role in determining cisplatin sensitivity [27, 28]. Activators of PKC sensitized both 2008  and HeLa cells  to cisplatin. Furthermore cisplatin resistance was associated with increase in novel PKC and decrease in conventional PKC [29, 30]. It remains to be seen if NSC109268 influences the PKC signaling pathway.
NSC109268 may also increase cisplatin sensitivity by facilitating its uptake or decreasing repair of cisplatin-induced DNA damage. Although cisplatin is believed to enter cells via passive diffusion, it has been reported that a fraction of cisplatin enters cells via the plasma membrane copper transporter CTR1 [31, 32]. Following internalization, both copper and cisplatin were shown to cause downregulation of CTR1 in ovarian cancer cells by the proteasome-mediated pathway . NSC109268 contains two copper ions and it was shown to inhibit 20S proteasome . Since loss of CTR1 can contribute to cisplatin resistance , it is conceivable that NSC109268 inhibits degradation of CTR1 by cispatin resulting in higher intracellular levels of cisplatin and consequently increase in cisplatin-induced cell death. Future studies should determine how NSC109268 attenuates cisplatin resistance via p53-independent mechanisms. Nevertheless, the observation that NSC109268 can partially overcome cisplatin resistance is significant. Since NSC compound can be easily synthesized, it could be used as an adjuvant to cisplatin-based therapy.
The present study demonstrates that NSC109268 enhances the sensitivity of cisplatin-resistant ovarian cancer 2008/C13* cells to cisplatin. While the induction of p53 by cisplatin or combination of NSC109268 and cisplatin correlates with increased cellular sensitivity to cisplatin, knockdown of p53 had no effect on cisplatin sensitization by NSC109268. Thus, NSC109268 potentiates cisplatin sensitivity via p53-independent mechanism(s). NSC109268 can be used in combination with cisplatin to circumvent cisplatin resistance.
Cisplatin, MTT and monoclonal antibody to actin were purchased from Sigma (St. Louis, MO). Monoclonal antibodies to p53 and GAPDH were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA), and monoclonal antibodies to PARP and p53 were obtained from Pharmingen (San Diego, CA). siRNA SMARTpool against p53, and non-targeting SMARTpool siRNA were obtained from Dharmacon (Lafayette, CO). Horseradish peroxidase-conjugated goat anti-mouse and donkey anti-rabbit antibodies were obtained from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Polyvinylidene difluoride membrane was from Millipore (Bedford, MA), and enhanced chemiluminescence detection kit was from Amersham (Piscataway, NJ). Lipofectamine 2000 transfection reagent and YO-PRO-1 were obtained from Invitrogen (Carlsbad, CA). Propidium Iodide was purchased from Molecular Probes (Eugene, OR). NSC109268 was provided by the Developmental Therapeutics Branch of the National Cancer Institute, and was also custom-synthesized by Omm Scientifc, Dallas, TX.
Human ovarian cancer 2008 cells and cisplatin-resistant variant 2008/C13* cells developed by Dr. Stephen B. Howell were obtained from the University of California San Diego. Cells were maintained in RPMI 1640 supplemented with 5% heat-inactivated FBS and 2 mmol/L glutamine. Human cervical carcinoma HeLa cells and its cisplatin-resistant variants (HeLa/CP)  were maintained in DMEM supplemented with 10% heat-inactivated fetal bovine serum and 2 mmol/L glutamine. Cells were kept in a humidified incubator at 37°C with 95% air and 5% CO2.
Assessment of cell viability by MTT Assay
Exponentially growing cells were plated in microtiter plates and incubated at 37°C in 5% CO2. The following day, cells were pretreated with or without NSC109268 and cisplatin as indicated in the text. The number of viable cells was determined using the dye MTT as previously described (5).
Assesment of cell death by YO-PRO-1/propidium iodide (PI) assay
Cells were labeled with 0.5 μM Yo-Pro-1 and 2 μM PI and incubated at 37°C for 15 min. Labeling of the cells was visualized using a Zeiss Axiovert 40 inverted microscope with the AxioVision Rel 4.6 software (Zeiss, Göttingen, Germany).
Equivalent amounts of protein from total cellular extracts were electrophoresed by SDS-PAGE and transferred electrophoretically to a poly(vinylidene difluoride) membrane. Immunoblot analyses were performed as described previously .
Knockdown of p53 by siRNA
Control siRNA or siRNA targeted against p53 were introduced into cells using Lipofectamine 2000 (Invitrogen) and manufacturer's protocol as previously described . Briefly, cells were seeded one day before transfection. Forty-eight hour following siRNA transfection, cells were treated with NSC109268 and cisplatin as indicated in the text and processed for Western blot analysis.
Sherman SE, Gibson D, Wang AH, Lippard SJ: X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH3)2(d(pGpG))]. Science 1985, 230:412–417.
Wang D, Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307–320.
Kerr JF, Winterford CM, Harmon BV: Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994, 73:2013–2026.
Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003, 22:7265–7279.
Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer 2009, 9:714–723.
Portugal J, Bataller M, Mansilla S: Cell death pathways in response to antitumor therapy. Tumori 2009, 95:409–421.
Vazquez A, Bond EE, Levine AJ, Bond GL: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 2008, 7:979–987.
Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594–604.
Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307–310.
Hoppe-Seyler F, Butz K: Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53. J Virol 1993, 67:3111–3117.
Jain D, Patel N, Shelton M, Basu A, Roque R, Siede W: Enhancement of cisplatin sensitivity by NSC109268 in budding yeast and human cancer cells is associated with inhibition of S-phase progression. Cancer Chemother Pharmacol 2010, in press.
Schuijer M, Berns EM: TP53 and ovarian cancer. Hum Mutat 2003, 21:285–291.
Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I, et al.: Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001, 7:2984–2997.
Buttitta F, Marchetti A, Gadducci A, Pellegrini S, Morganti M, Carnicelli V, Cosio S, Gagetti O, Genazzani AR, Bevilacqua G: p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer 1997, 75:230–235.
Lavarino C, Pilotti S, Oggionni M, Gatti L, Perego P, Bresciani G, Pierotti MA, Scambia G, Ferrandina G, Fagotti A, et al.: p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000, 18:3936–3945.
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, et al.: A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996, 56:689–693.
De Feudis P, Debernardis D, Beccaglia P, Valenti M, Graniela Sire E, Arzani D, Stanzione S, Parodi S, D'Incalci M, Russo P, Broggini M: DDP-induced cytotoxicity is not influenced by p53 in nine human ovarian cancer cell lines with different p53 status. Br J Cancer 1997, 76:474–479.
Li J, Wood WH, Becker KG, Weeraratna AT, Morin PJ: Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells. Oncogene 2007, 26:2860–2872.
Branch P, Masson M, Aquilina G, Bignami M, Karran P: Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene 2000, 19:3138–3145.
Yazlovitskaya EM, DeHaan RD, Persons DL: Prolonged wild-type p53 protein accumulation and cisplatin resistance. Biochem Biophys Res Commun 2001, 283:732–737.
Horowitz J: Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr Opin Mol Ther 1999, 1:500–509.
Kigawa J, Sato S, Shimada M, Takahashi M, Itamochi H, Kanamori Y, Terakawa N: p53 gene status and chemosensitivity in ovarian cancer. Hum Cell 2001, 14:165–171.
Song K, Cowan KH, Sinha BK: In vivo studies of adenovirus-mediated p53 gene therapy for cis-platinum-resistant human ovarian tumor xenografts. Oncol Res 1999, 11:153–159.
Johnson CL, Lu D, Huang J, Basu A: Regulation of p53 stabilization by DNA damage and protein kinase C. Mol Cancer Ther 2002, 1:861–867.
Pestell KE, Hobbs SM, Titley JC, Kelland LR, Walton MI: Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. Mol Pharmacol 2000, 57:503–511.
Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573–584.
Basu A, Teicher BA, Lazo JS: Involvement of protein kinase C in phorbol ester-induced sensitization of HeLa cells to cis-diamminedichloroplatinum(II). J Biol Chem 1990, 265:8451–8457.
Isonishi S, Andrews PA, Howell SB: Increased sensitivity to cis-diamminedichloroplatinum(II) in human ovarian carcinoma cells in response to treatment with 12-O-tetradecanoylphorbol 13-acetate. J Biol Chem 1990, 265:3623–3627.
Basu A, Weixel K, Saijo N: Characterization of the protein kinase C signal transduction pathway in cisplatin-sensitive and -resistant human small cell lung carcinoma cells. Cell Growth Differ 1996, 7:1507–1512.
Basu A, Weixel KM: Comparison of protein kinase C activity and isoform expression in cisplatin-sensitive and -resistant ovarian carcinoma cells. Int J Cancer 1995, 62:457–460.
Ishida S, Lee J, Thiele DJ, Herskowitz I: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 2002, 99:14298–14302.
Safaei R, Howell SB: Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005, 53:13–23.
Holzer AK, Katano K, Klomp LW, Howell SB: Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 2004, 10:6744–6749.
Daniel KG, Gupta P, Harbach RH, Guida WC, Dou QP: Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem Pharmacol 2004, 67:1139–1151.
Huang J, Mohanty S, Basu A: Cisplatin resistance is associated with deregulation in protein kinase C-delta. Biochem Biophys Res Commun 2004, 316:1002–1008.
Basu A, Akkaraju GR: Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C. Biochemistry 1999, 38:4245–4251.
Sivaprasad U, Shankar E, Basu A: Downregulation of Bid is associated with PKCepsilon-mediated TRAIL resistance. Cell Death Differ 2007, 14:851–860.
NSC109268 was generously provided by the Developmental Therapeutics Branch of the National Cancer Institue (NCI). The authors gratefully acknowledge Late Rajiv Paranandi for his assistance with fluorescence microscopy. This work was supported by the grant CA071727 (AB) from the NIH/NCI and Joe and Jessie Crump Fund for Medical Education.
The authors declare that they have no competing interests.
ES performed Western blot analysis, siRNA knockdown and Yo-Pro-1/PI staining to determine the involvement of p53 in cisplatin sensitization. CB performed MTT assay to compare the effect of NSC109268 on cisplatin sensitization in 2008 and 2008/C13* cells. BA performed similar study with HeLa and HeLa/CP cells. WS first identified NSC109268 during yeast-based genetic screening and provided intellectual input in this collaborative study. AB designed experiments, analysed data and prepared manuscript. All authors read and approved the final manuscript.